Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Nikole Wollerstein who wrote (362)	5/21/1998 8:32:00 AM
From: Curtis Frazier	Respond to of 705

I have the same concerns. This information is not new, but yet the market really ran on this one. When will the CEO appear on CNBC???

To: Nikole Wollerstein who wrote (362)	5/21/1998 9:36:00 AM
From: NeuroInvestment	Read Replies (3) \| Respond to of 705

There are a couple of assertions here that are inaccurate, or unestablished: 1) AIT-082's role in boosting endogenous neurotrophic factors has not been implicated as then boosting beta-amyloid production. It is true that AIT-082 does not appear to address the etiological substrate for AD (thus I believe labeling as a 'cure' is both premature and perhaps inaccurate, though we will have to see how effectively it arrests the degenerative process)....it would seem to function as a trophic inducer which counterbalances the neurodegeneration of AD. It would seem to act midway through the AD process, not (so far as we know) affecting the development of beta-amyloidosis which is earlier. AIT-082 is earlier in the sequence than those approaches which seek to enhance memory potentiation at the post-synaptic level (most crudely and ineffectively via cholinesterases, such as Aricept....perhaps in a more sophisticated and effective way via Cortex's Ampakines). However, its rapid effect in the Phase I trials suggests another mechanism as well, since slowing neurodegeneration alone should not 'improve' memory over just a couple of hours. 2) The NEOT Phase I trials were with Alzheimers patients, and thus have more meaning than the usual Phase I safety tests. However,the neuropsych measures used were quick screens and not comprehensive, and it is this area that the Phase II studies must explore, as well as the effects of repeated dosing. NeuroInvestment (www.neuroinv.com)